<DOC>
	<DOCNO>NCT01380951</DOCNO>
	<brief_summary>Antiviral treatment Chronic Hepatitis B ( CHB ) patient liver cirrhosis compulsory effective . Telbivudine , superior lamivudine treatment CHB , consider appropriate antiviral treatment CHB patient liver cirrhosis .</brief_summary>
	<brief_title>Safety Efficacy Telbivudine Liver Cirrhosis Patients With Chronic Hepatitis B ( CHB )</brief_title>
	<detailed_description>Antiviral therapy CHB patient liver cirrhosis compulsory effective . Diseases development prevent delayed virus depress successfully . Lamivudine often use usually good efficacy . However , lamivudine resistance virus mutation happen lot . Telbivudine , superior lamivudine treatment CHB , consider appropriate antiviral treatment CHB patient liver cirrhosis .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>liver cirrhosis CHB without history antiviral therapy discontinue antiviral therapy 6 month patient compensate liver cirrhosis : HBV DNA≥4log copies/ml HBeAg positive , HBV DNA≥3log copies/ml HBeAg negative patient uncompensated liver cirrhosis : HBV DNA positive coinfection HCV , HDV HIV AFP≥100mg/L HCC diagnose iconography severe cardiovascular , respiratory endocrinology disease autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>liver cirrhosis</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>antiviral therapy</keyword>
	<keyword>telbivudine</keyword>
</DOC>